An investigational fixed combination of cagrilintide and semaglutide studied in metabolic and weight-management trials. This record separates established identity and source-linked research context from protocol or commercial fields that are not yet supportable.
FEMETRIC RECORD · PUBLICCagriSema
Weight ManagementAppetiteGlucose / Insulin
Status
Clinical Development
Related
4
Sources
1
UPDATED 2026-09-13
01
Protocol references
SOURCE-LINKED
PUBLISHED STUDY
Source-linked research context
No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.
Route
Subcutaneous
Frequency
See indexed source
Duration
Not indexed
Escalation
Not established
Stage detail pending source extractionStarting and target doses are indexed. Intermediate steps are intentionally not inferred.
PUBLISHED STUDYNew England Journal of Medicine, 2025Verified 2026-09-13
CagriSema combines amylin-analogue and GLP-1 receptor pathways. Femetric treats the combination as a distinct record rather than adding monotherapy findings together.
Mechanism summaries are stored with field-level source provenance for editorial audit.
07
Related research goals
08
Related peptides
01PEPTIDE
Cagrilintide
An investigational long-acting amylin analogue studied alone and with semaglutide for weight management.
Weight ManagementAppetiteFat Loss
02PEPTIDE
Semaglutide
An approved GLP-1 receptor agonist with formulation- and indication-specific evidence for diabetes, weight management and cardiovascular outcomes.
Weight ManagementAppetiteGlucose / Insulin
03PEPTIDE
Tirzepatide
An approved dual GIP and GLP-1 receptor agonist studied across type 2 diabetes, obesity and cardiometabolic outcomes.
Weight ManagementAppetiteGlucose / Insulin
04PEPTIDE
Retatrutide
An investigational GIP, GLP-1 and glucagon receptor agonist studied for obesity and metabolic outcomes.